13 healthcare companies reach $1B valuations this year

Thirteen healthcare companies have reached $1 billion in valuation this year––an especially notable achievement as the U.S. economy approaches a recession and investors pull back.

Business Insider reported on the 13 companies, underlying the decline in digital health investments this year. Digital-health startups raked in $6 billion in the first quarter of 2022, compared to $7.3 billion raised in the fourth quarter of 2021, Insider reported. Despite the decline, funding is still elevated above pre-pandemic levels, underscoring the huge interest in digital health among investors. 

News of the sky-high valuations also comes as healthcare is still evolving to meet the demands of the COVID-19 pandemic. As workforces and hospital and health system resources are stretched, telehealth has seen increased demand since the start of the pandemic––and many healthcare organizations have launched new virtual health programs.

 

Here are the 13 healthcare companies that made Insider’s list:

  • NexHealth - $1 billion valuation
  • Wheel - $1.02 billion valuation
  • Omada Health - $1.03 billion valuation
  • IntelyCare - $1.1 billion valuation
  • Viz.ai - $1.2 billion valuation
  • Biofourmis - $1.3 billion valuation
  • Clipboard Health - $1.3 billion valuation 
  • Clarify Health - $1.5 billion valuation
  • Athelas - $1.56 billion valuation
  • Transcarent - $1.62 billion valuation
  • BostonGene - $2.15 billion valuation
  • Oura Health - $2.55 billion valuation
  • Somatus - $2.56 billion valuation

Click the link below for the full story:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.

“Without a more concrete and stable policy on these tariffs from the current American administration, it is likely that most manufacturers will be forced to continuously change their internal forecasts and production plans," one analyst said.